Peptide exchange in MHC molecules
- PMID: 10631949
- DOI: 10.1111/j.1600-065x.1999.tb01368.x
Peptide exchange in MHC molecules
Abstract
Major histocompatibility complex (MHC)-encoded glycoproteins bind peptide antigens through non-covalent interactions to generate complexes that are displayed on the surface of antigen-presenting cells (APC) for recognition by T cells. Peptide-binding site occupancy is necessary for stable assembly of newly synthesized MHC proteins and export from the endoplasmic reticulum (ER). The MHC class II antigen-processing pathway provides a mechanism for presentation of peptides generated in the endosomal pathway of APC. The chaperone protein, invariant chain, includes a surrogate peptide that stabilizes newly synthesized class II molecules during transport to endosomal compartments. The invariant chain-derived peptide must be replaced through a peptide exchange reaction that is promoted by acidic pH and the MHC-encoded co-factor HLA-DM. Peptide exchange reactions are not required for presentation of antigens by MHC class I molecules because they bind antigens during initial assembly in the ER. However, exchange reactions may play an important role in editing the repertoire of peptides presented by both class II and class I molecules, thus influencing the specificity of immunity and tolerance.
Similar articles
-
The role of H2-O and HLA-DO in major histocompatibility complex class II-restricted antigen processing and presentation.Immunol Rev. 1999 Dec;172:255-66. doi: 10.1111/j.1600-065x.1999.tb01370.x. Immunol Rev. 1999. PMID: 10631951 Review.
-
The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules.Immunol Rev. 1999 Dec;172:267-78. doi: 10.1111/j.1600-065x.1999.tb01371.x. Immunol Rev. 1999. PMID: 10631952 Review.
-
Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression.Immunol Rev. 2005 Oct;207:242-60. doi: 10.1111/j.0105-2896.2005.00306.x. Immunol Rev. 2005. PMID: 16181341 Review.
-
HLA-DM and the MHC class II antigen presentation pathway.Immunol Res. 1999;20(3):195-205. doi: 10.1007/BF02790403. Immunol Res. 1999. PMID: 10741860 Review.
-
Assembly and transport of MHC class II molecules.New Biol. 1992 May;4(5):441-7. New Biol. 1992. PMID: 1515409 Review.
Cited by
-
Regulated expression of human histocompatibility leukocyte antigen (HLA)-DO during antigen-dependent and antigen-independent phases of B cell development.J Exp Med. 2002 Apr 15;195(8):1053-62. doi: 10.1084/jem.20012066. J Exp Med. 2002. PMID: 11956296 Free PMC article.
-
Molecular subsets in the gene expression signatures of scleroderma skin.PLoS One. 2008 Jul 16;3(7):e2696. doi: 10.1371/journal.pone.0002696. PLoS One. 2008. PMID: 18648520 Free PMC article.
-
Biomolecular cytokine therapy.Pathol Oncol Res. 2003;9(1):24-9. doi: 10.1007/BF03033710. Epub 2003 Apr 18. Pathol Oncol Res. 2003. PMID: 12704443 Review.
-
HIV-1-Infected CD4+ T Cells Present MHC Class II-Restricted Epitope via Endogenous Processing.J Immunol. 2022 Sep 1;209(5):864-873. doi: 10.4049/jimmunol.2200145. Epub 2022 Aug 5. J Immunol. 2022. PMID: 36130133 Free PMC article.
-
The expression of HLA-DO (H2-O) in B lymphocytes.Immunol Res. 2004;29(1-3):19-28. doi: 10.1385/IR:29:1-3:019. Immunol Res. 2004. PMID: 15181267 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials